Procept Biorobotics Corp Stock Price, News & Analysis

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced on April 28, 2022, that Aetna US Healthcare has updated its coverage policy to positively include Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, effective April 26, 2022. Additionally, Independence Blue Cross Blue Shield extended its coverage to include Aquablation therapy for approximately 4 million members, starting April 25, 2022. The CEO highlighted the growing adoption of Aquablation therapy, which now has five of the seven largest U.S. commercial payors approving its coverage.

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) will report its first-quarter 2022 financial results on May 5, 2022, after market close. The company focuses on urological solutions, primarily with its AquaBeam Robotic System, which offers effective treatment for benign prostatic hyperplasia (BPH). The management will hold a conference call at 1:30 p.m. PT for investors. A recording will be accessible on the company’s website for 90 days. Additionally, PROCEPT will participate in the Bank of America Healthcare Conference on May 11, presenting at 2:00 p.m. PT.

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced an in-person investor event on May 13, 2022, during the American Urology Association Annual Meeting in New Orleans. The event will feature insights from the executive team and a surgeon panel discussing the AquaBeam Robotic System. PROCEPT's AquaBeam technology focuses on treating benign prostatic hyperplasia (BPH), a condition affecting around 40 million men in the U.S. The company has established a robust clinical evidence base, comprising nine studies and over 100 peer-reviewed publications supporting Aquablation therapy outcomes.

PROCEPT BioRobotics (Nasdaq: PRCT) reported strong financial results for Q4 and full year 2021, with revenues reaching $10.1 million for Q4 and $34.5 million for the full year, up from $3.2 million and $7.7 million in 2020. The company's U.S. system and rental revenue increased to $5.0 million in Q4. Despite a net loss of $18.3 million in Q4, the company issued revenue guidance of $54.0 million to $58.0 million for 2022. Key achievements included a nearly doubled sales force and positive results from the WATER Study supporting Aquablation therapy.

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced it will report its financial results for the fourth quarter and full year 2021 on March 8, 2022, before market open. A conference call will be held at 5:00 a.m. PT / 8:00 a.m. ET. Investors can listen by calling (800) 306-0005 domestically or (209) 905-5968 internationally. The AquaBeam Robotic System, designed for minimally-invasive urologic surgery, targets benign prostatic hyperplasia, affecting around 40 million men in the U.S. There is a strong clinical evidence base supporting Aquablation therapy.

PROCEPT BioRobotics Corporation announced positive five-year outcomes from its WATER study, affirming the efficacy of Aquablation therapy compared to TURP for treating benign prostatic hyperplasia (BPH). The study showed a 51% lower retreatment rate, with significant improvements in IPSS scores—15.1 points for Aquablation vs. 13.2 for TURP. In particular, larger prostates (≥50 ml) exhibited even greater benefits, suggesting a shift in BPH treatment paradigms. The results indicate Aquablation's potential as a preferred option, emphasizing safety and durability across varying prostate sizes.

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced its upcoming participation in two major investor conferences. The first is the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 2:00 pm PT / 5:00 pm ET, followed by the 42nd Annual Cowen Health Care Conference on March 9, 2022, at 9:50 am PT / 12:50 pm ET. A live webcast and archive will be accessible on the company's website for 90 days post-event. PROCEPT specializes in robotic solutions for urology, particularly the AquaBeam Robotic System, addressing benign prostatic hyperplasia (BPH), impacting around 40 million men in the U.S.

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced the installation of five AquaBeam Robotic Systems across Northside Health Systems in Georgia, marking a significant expansion of their surgical robotics program. The AquaBeam system utilizes heat-free waterjet technology for the treatment of benign prostatic hyperplasia (BPH), a common prostate disease affecting 40 million men in the U.S. The therapy aims to provide a safe and effective treatment option tailored to patients’ needs, enhancing access to innovative surgical techniques.

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced preliminary unaudited revenues for Q4 and FY 2021, projecting revenue between $9.8 million and $10.1 million for Q4, up from <$3.2 million> in the previous year. Total FY 2021 revenue is expected to be between $34.1 million and $34.4 million, compared to <$7.7 million> in FY 2020. Revenue growth is attributed to increased sales of their AquaBeam Robotic System and successful adoption of Aquablation therapy. Full financial results will be released in March 2022.